Mutated factor X polypeptides and uses thereof for the treatment of haemophilia
US10655119B2 · kind B2 · utility
1Cited by
0References
7Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jul 26, 2016 |
| Grant date | May 19, 2020 |
| Priority date | — |
| Expiry date | Sep 19, 2036 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to mutated factor (FX) polypeptides and uses thereof for the treatment of haemophilia. In particular, the present invention relates to a mutated factor X (FX) polypeptide which comprises a heavy chain wherein at least one amino acid residue at position 441 and/or 448 of SEQ ID NO: 1 is mutated.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.